Prashant Kapoor, MD, and Shaji Kumar, MD, on Bortezomib, Lenalidomide, Dexamethasone With or Without Elotuzumab for Multiple Myeloma

Posted: Wednesday, June 24, 2020

Prashant Kapoor, MD, and Shaji Kumar, MD, both of the Mayo Clinic, discuss phase II results from the SWOG-1211 trial, which support the role of proteasome inhibitor and/or immunomodulatory combination maintenance therapy for patients with newly diagnosed, high-risk multiple myeloma.